Immunocore vs Tarsus Pharmaceuticals
Tarsus Pharmaceuticals reported revenue of $451 million in fiscal 2025, about the same as Immunocore's $400 million in fiscal 2025. Immunocore's revenue grew 28.9% in its latest year, and Tarsus Pharmaceuticals' grew 146.7%. Immunocore had an operating margin of -11.3%, against -15.7% at Tarsus Pharmaceuticals. Free cash flow was −$15 million at Immunocore and −$22 million at Tarsus Pharmaceuticals.
Side by side
| Immunocore | Tarsus Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $400M | $451M |
| Revenue growth | 28.9% | 146.7% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | 98.7% | — |
| Operating margin | −11.3% | −15.7% |
| Net margin | −8.9% | −14.7% |
| Free cash flow | −$15M | −$22M |
| Free cash flow margin | −3.8% | −4.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 0.7% | 11.1% |
| Last close | $26.63 | $77.67 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $5.6 million | sold $20.8 million |
| Piotroski F-score | — | 4 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ImmunocoreTarsus Pharmaceuticals
Operating margin
Percent of revenue
ImmunocoreTarsus Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ImmunocoreTarsus Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Immunocore and Tarsus Pharmaceuticals pages.